Solriamfetol for binge-eating disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Apr 2024: Trial started, NCT06413433
  2. 14 May 2024: Trial registered, NCT06413433

The trials

NCT06413433: Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

State
Under way
Phase
Phase 3
People
450 planned
Started
26 Apr 2024
Primary completion
Dec 2026
Arms
Solriamfetol 150 mg, Solriamfetol 300 mg
Results
None posted
  1. 26 Apr 2024: Trial started
  2. 14 May 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Sunosi, Solriamfetol 150 mg, Solriamfetol 300 mg.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.